Nephros financials
$3.89−3.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $18.8M | $14.2M | $14.2M | $10.0M | $10.2M | $8.6M | $10.3M |
| Gross profit | $11.6M | $8.7M | $8.4M | $4.7M | $5.6M | $4.9M | $6.1M |
| Gross margin | 61.9% | 61.6% | 59.0% | 47.4% | 55.1% | 57.4% | 58.9% |
| Operating income | $1.1M | $6.0K | -$1.6M | -$4.3M | -$3.3M | -$4.3M | -$3.2M |
| Net income | $1.2M | $74.0K | -$1.6M | -$7.4M | -$4.1M | -$4.8M | -$3.4M |
| Net margin | 6.4% | 0.5% | −11.1% | −74.0% | −40.2% | −55.7% | −33.1% |
| Diluted EPS | $0.11 | $0.01 | $-0.15 | $-0.73 | $-0.41 | $-0.52 | $-0.45 |
| EBITDA | $1.3M | $143.0K | -$1.4M | -$4.0M | -$3.0M | -$4.3M | -$3.1M |
| Operating cash flow | $1.6M | -$492.0K | $827.0K | -$3.2M | -$1.4M | -$6.9M | -$2.1M |
| Free cash flow | $1.6M | -$547.0K | $752.0K | -$3.4M | -$1.5M | -$7.1M | -$2.1M |
| Diluted shares | 11.0M | 10.6M | 10.4M | 10.3M | 10.0M | 9.1M | 7.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.4M | $3.8M | $4.3M | $3.6M | $7.0M | $8.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $72.0K | $343.0K | $1.1M |
| Total assets | $13.6M | $11.2M | $11.9M | $11.0M | $17.6M | $18.5M |
| Total liabilities | $3.4M | $2.6M | $3.5M | $2.1M | $2.9M | $2.9M |
| Shareholders' equity | $10.2M | $8.6M | $8.4M | $8.9M | $14.7M | $15.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology